The need to develop an insulin delivery system that can closely mimic physiologically induced changes in prandial insulin release has been a major research target since the discovery of insulin. The challenges facing existing insulin delivery systems, related to relatively slow pharmacokinetics and pharmacodynamics, have been further highlighted by rapid advances in diabetes technology and progress in artificial pancreas research. Despite the growing interest in alternative routes of insulin administration, the subcutaneous route remains-at least for now-the preferred route for insulin administration. In this article, we review efforts aimed at developing subcutaneously injected ultrafast-acting insulin and measures aimed at enhancing insulin absorption, focusing on local warming devices.
INTRODUCTION
In people with normal glucose tolerance, the endogenous insulin profile combines constant pulsatile basal insulin production with prandial insulin secretion. The main role of basal insulin is to limit hepatic glucose production while maintaining adequate glucose for cerebral function. Following a mixed meal, the rise in blood glucose is rapidly sensed by beta cells in the pancreas, resulting in insulin release, over two phases, into the portal circulation and a rapid rise in circulating insulin levels. This results in suppression of hepatic glucose production followed by stimulation of glucose utilisation in the main insulin-dependent tissues (e.g. skeletal muscle and adipose tissue), preventing a postprandial rise in blood glucose levels [1] .
In healthy nonobese adults, insulin is secreted at a basal rate of 0.5-1 U per hour, resulting in plasma concentrations of 5-15 mU/ L in fasting conditions [1] . Following a mixed meal, plasma insulin levels reach half of the maximal concentration in approximately 16-18 min and peak at 60-80 mU/L within 45 min before returning to baseline 2-4 h later [2] .
Since the discovery of insulin in 1922, there have been continuous advances in the field of insulin therapy, with the aim being to develop insulin delivery systems that can mimic physiological insulin secretion. However, several factors affect the pharmacokinetics (PK) and pharmacodynamics (PD) of exogenously administered insulin. These include insulin formulation, dose and concentration, as well as mode of administration, injection site, injection depth, infusion site age, exercise, local massage, temperature and individual variation in obesity, age, and smoking [2] [3] [4] [5] [6] [7] .
The subcutaneous tissue structure limits the spread of injectable insulin and its absorption into the systemic circulation. This impacts insulin PK and PD with delayed onset, a The introduction in the 1990s of rapid-acting insulin analogues (RAIAs), with insulin absorption and a metabolic effect that are accelerated compared to regular human insulin (RHI), has resulted in improved diabetes management. The faster onset and peak of action allow the time interval between insulin injection and meals to be shortened and postprandial glycaemic excursions to be reduced [11] . The shorter duration of action also reduces the risk of hypoglycaemia [12] .
Evidence from meta-analyses also shows the beneficial effect of RAIAs compared to RHI in reducing HbA1c in both type 1 and type 2 diabetes [13, 14] . Moreover, the earlier rise in insulin levels obtained with RAIAs, simulating the first-phase insulin response, may have a more pronounced impact on the suppression of hepatic glucose production with a subsequent significant reduction in PPG [15] . Current RAIAs (lispro, aspart and glulisine) have similar PK/PD profiles, with the onset of insulin exposure occurring in 5-15 min, a peak at 45-60 min and an overall duration of about 3-4 h [11] . Despite the benefits provided by RAIAs, these formulations remain slower than physiological insulin secretion since their glucose-lowering effect can take 2-3 h to peak and can last for 5-6 h [16] . Several studies have demonstrated that an injection to meal time interval of 15-20 min was required to shift the action profile of RAIAs to achieve a better overlap with the postprandial glucose profile and optimally reduce PPG excursions without increasing the risk of hypoglycaemia [17] [18] [19] .
However, inconvenience and the increased risk of periprandial hypoglycaemia are likely to be a barrier to an early injection to meal interval in reality. Furthermore, the relatively slow PK/PD of RAIAs represent a challenge to artificial pancreas algorithms. The delay between the start of a meal and rise of interstitial fluid glucose, which triggers automatic insulin delivery, is exacerbated by the slow PK/PD of existing insulin formulations, resulting in large PPG excursions. Therefore, the development of novel formulations and methods that modify insulin PK/PD to mimic the endogenous insulin profile remains a major research target.
Euglycaemic glucose-clamp studies are frequently used to assess PK (insulin exposure) and PD (insulin action) of insulins. The serum insulin concentration reflects insulin exposure, while glucose infusion rate (GIR) reflects insulin action. The onset, time to peak and offset are represented by early t 50% , t max and late t 50% , respectively. Other important parameters include maximum insulin concentration (C max ), maximum GIR (GIR max ) and area under the curve (AUC). The AUC for insulin represents the overall bioavailability of injected insulin, while the AUC for GIR represents the overall glucose-lowering effect [1] .
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. The use of jet spray injectors has also been investigated as a method to enhance insulin absorption [29, 30] . Initially designed for people with needle phobia, jet spray injectors work by sending a fine spray of insulin through the skin into subcutaneous tissue using a high-velocity jet, allowing insulin delivery without the need to use a needle to puncture the skin. They enhance insulin absorption by mechanically dispersing insulin into a large area of the subcutaneous tissue. The use of jet injectors is limited by the need for training, their cost and the potential discomfort caused by the high-velocity jet.
INNOVATIONS AIMING TO ENHANCE ABSORPTION OF SUBCUTANEOUSLY INJECTED INSULIN
This article reviews evidence relating to the use of local warming devices (InsuPatch and InsuPad) as tools to increase the absorption of subcutaneously injected insulin and enhance its PK/PD profile. A literature review was performed using PubMed, the Cochrane Library database and Web of Science to identify relevant studies.
Search terms used were ''insulin absorption'', ''insulin pharmacokinetics'' and ''insulin pharmacodynamics'' followed by a keyword search for ''local warming'' and ''local heating''.
Other search terms used were ''InsuPad'' and ''InsuPatch''.
LOCAL WARMING DEVICES

Principle and Mechanism of Action
The effect of ambient temperature on insulin PK has been recognised. Exposure to a sauna at 85°C InsuPad is CE marked and is currently approved for marketing in a few countries, including
Israel, Canada and Germany. However, it is not FDA approved yet.
Studies Evaluating the Effects of Local
Warming Devices
Evaluation of InsuPatch
The effects of InsuPatch on the PK and PD of insulin were evaluated in 17 adults with type 1 diabetes (using insulin lispro or aspart). In this open-label randomised crossover study, subjects were randomised to InsuPatch or control (using an infusion set without InsuPatch) arms before crossover and underwent a meal tolerance test In an open-label randomised crossover meal tolerance study, the effect of InsuPad on PPG excursions was evaluated in subjects with type 2 diabetes treated with basal-bolus insulin therapy. Glucose profiles demonstrated a 40% reduction in the AUC of the PPG excursion during the first 2 h following the meal when InsuPad was used (Fig. 3) . Insulin PK (Fig. 4) showed that the use of InsuPad resulted in an One of the acknowledged limitations of the Barmer study was the reliability of self-reported prandial insulin dose information. Aiming to confirm the findings of the Barmer study and to demonstrate the noninferiority of the reduced prandial insulin dose observed in the intervention group, a substudy of the original Barmer study involving all subjects from one study site was performed. Thirty-two subjects A long-term follow-up open-label extension of the Barmer study was performed in 52 patients who could be contacted after a minimum of 13 months (mean usage time: 17.8 months, range: 13-21 months). In those subjects, the initial benefits observed with InsuPad use were maintained over 18 months.
HbA1c was stable at 6.4%, as was body weight. However, the total daily insulin dose was further reduced compared to baseline. Only 2 people stopped using the device because of a persistent skin reaction to the adhesive [48] . 
